Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/304% below fair value
$32.98+0.23 (+0.70%)
Close on Nov 17, 2026Market cap $1.01BP/E –Yield 0.00%
Castle Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Castle Biosciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $58.29M, up 16.3% year over year. For fiscal 2025 it was $51.85M, down 0.4% from the year before. The highest annual figure on record is $53.62M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.85M | -0.4% |
| FY2024 | Dec 31, 2024 | $52.04M | -2.9% |
| FY2023 | Dec 31, 2023 | $53.62M | +19.4% |
| FY2022 | Dec 31, 2022 | $44.90M | +51.5% |
| FY2021 | Dec 31, 2021 | $29.65M | +123.6% |
| FY2020 | Dec 31, 2020 | $13.26M | +79.5% |
| FY2019 | Dec 31, 2019 | $7.39M | +52.1% |
| FY2018 | Dec 31, 2018 | $4.85M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $15.81M | +22.0% |
| Q2 FY2026 | Jun 30, 2026 | $14.54M | +13.7% |
| Q1 FY2026 | Mar 31, 2026 | $14.43M | +14.6% |
| Q4 FY2025 | Dec 31, 2025 | $13.52M | +14.8% |
| Q3 FY2025 | Sep 30, 2025 | $12.96M | +5.2% |
| Q2 FY2025 | Jun 30, 2025 | $12.79M | -9.5% |
| Q1 FY2025 | Mar 31, 2025 | $12.59M | -8.8% |
| Q4 FY2024 | Dec 31, 2024 | $11.77M | -9.4% |
| Q3 FY2024 | Sep 30, 2024 | $12.32M | -4.6% |
| Q2 FY2024 | Jun 30, 2024 | $14.14M | +6.2% |
| Q1 FY2024 | Mar 31, 2024 | $13.81M | -4.1% |
| Q4 FY2023 | Dec 31, 2023 | $12.99M | +14.9% |
| Q3 FY2023 | Sep 30, 2023 | $12.92M | +18.5% |
| Q2 FY2023 | Jun 30, 2023 | $13.31M | +11.6% |
| Q1 FY2023 | Mar 31, 2023 | $14.39M | +33.8% |
| Q4 FY2022 | Dec 31, 2022 | $11.31M | +19.7% |
| Q3 FY2022 | Sep 30, 2022 | $10.91M | +45.4% |
| Q2 FY2022 | Jun 30, 2022 | $11.93M | +75.6% |
| Q1 FY2022 | Mar 31, 2022 | $10.76M | +82.1% |
| Q4 FY2021 | Dec 31, 2021 | $9.45M | +106.2% |
| Q3 FY2021 | Sep 30, 2021 | $7.50M | +145.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.79M | +151.2% |
| Q1 FY2021 | Mar 31, 2021 | $5.91M | +102.8% |
| Q4 FY2020 | Dec 31, 2020 | $4.58M | +45.0% |
| Q3 FY2020 | Sep 30, 2020 | $3.06M | +101.8% |
| Q2 FY2020 | Jun 30, 2020 | $2.70M | +105.3% |
| Q1 FY2020 | Mar 31, 2020 | $2.91M | +109.0% |
| Q4 FY2019 | Dec 31, 2019 | $3.16M | +177.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.52M | +17.1% |
| Q2 FY2019 | Jun 30, 2019 | $1.32M | +13.6% |
| Q1 FY2019 | Mar 31, 2019 | $1.39M | – |
| Q4 FY2018 | Dec 31, 2018 | $1.14M | – |
| Q3 FY2018 | Sep 30, 2018 | $1.29M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.16M | – |
See a number that looks wrong?